Pharmaxis Limited (ASX:PXS)
has presented new analyses on the longer term benefits of its drug Bronchitol on cystic fibrosis sufferers.
The presentation at the European Cystic Fibrosis Society conference in Portugal, included the results of pooled studies with adult patients treated with Bronchitol showing significant improvement in lung function.
It also showed a 24 per cent reduction in patients requiring IV antibiotics, compared to those that received the best standard of care.
Pharmaxis CEO Gary Phillipssays the analysis highlights the value of the drug to healthcare systems in terms of cost-efficiency.
The company says it has completed pricing and reimbursement negotiations in Germany and the UK and is engaged with other countries in the EU, with announcements expected in the months ahead.
Pharmaxis posted a net loss of $20.7 million in the first half of this financial year.